Biotech Values

[poorgradstudent]

MYOK:

I'm still in wait and see mode. I remain unconvinced the company can effectively enrich their trials. I thought they were going to be very specific with their cardiomyopathy cohort (specific protein, specific mutation) but they seem to have moved away from that.

I like their approach of reducing the force of contraction better than CYTK's aim to increase. However, I'm not ready to place any money to back their efforts.

By the way . I found many of your posts / opinions in 2016 to be proven correct .

When you have a lot of free darts to throw, it's easier to hit the dartboard!